More: Association for Research in Vision and Ophthalmology (ARVO) 2008 Annual Meeting

ARVO 2008: Glaucoma CME/CE

April 27, 2008 - May 1, 2008, Fort Lauderdale, Florida

Author Information and Disclosures

This activity is not sanctioned by, nor a part of, the Association for Research in Vision and Ophthalmology.

Release Date: May 27, 2008; Valid for credit through May 27, 2009

Credits Available
Physicians - maximum of 1.0 AMA PRA Category 1 Credit(s)™ for physicians;
Pharmacists - 1.0 ACPE continuing education credits for pharmacists (0.1 CEUs)

To participate in this internet activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the education content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View details.

Legal Disclaimer

The materials presented here do not reflect the views of Medscape or the companies providing unrestricted educational grants. These materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. All readers or continuing education participants should verify all information and data before treating patients or employing any therapies described in this educational activity.

The materials presented here were prepared by independent authors under the editorial supervision of Medscape and do not represent a publication of the Association for Research in Vision and Ophthalmology. These materials and the related activity are not sanctioned by the Association for Research in Vision and Ophthalmology or the commercial supporter of the conference and do not constitute an official part of that conference.

Copyright © 2008 Medscape.
Alcon
Learning Objectives
Upon completion of this activity, participants will be able to:
  1. Evaluate the risk of ocular toxicities from the use of antiglaucoma medications
  2. Discuss the latest advances in medical and surgical therapies for glaucoma
  3. Optimize screening techniques through an improved understanding of the mechanisms of glaucoma
Authors and Disclosures

Seth P. Epstein, MD
Disclosure: Seth P. Epstein, MD, has disclosed that he has received grants for clinical research from Alcon, Vistakon, and Inspire. Dr. Epstein has also disclosed that he has received grants for educational activities from Alcon.


Nathan Congdon, MD, MPH
Disclosure: Nathan Congdon, MD, MPH, has disclosed that he has received grants for clinical research and education activities from Reichert Instruments.


Charlotte Warren
Disclosure: Charlotte Warren has disclosed no relevant financial relationships.


 
Medscape
Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Medscape, LLC designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Contact This Provider

 
ACPE logoMedscape is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Medscape designates this continuing education activity for 1.0 contact hour(s) (0.1 CEUs) (Universal Program Number 461-000-08-040-H01-P).

Contact This Provider

All material on this website is protected by copyright, Copyright © 1994-2008 by Medscape. This website also contains material copyrighted by 3rd parties.